Stock 603739 QINGDAO VLAND BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-07 pm EDT 		5-day change 1st Jan Change
12.26 CNY -3.46% Intraday chart for Qingdao Vland Biotech INC. -7.33% -19.45%
May. 07 China stocks edge down; HK shares fall after 10-day winning streak RE
Apr. 25 Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,474 4,689 3,387 3,851 3,102 - -
Enterprise Value (EV) 1 3,474 4,689 3,387 3,851 3,102 3,102 3,102
P/E ratio 22.9 x 34.4 x 49.7 x 47.6 x 32.5 x 29.2 x 26.1 x
Yield - 0.86% 0.75% 0.66% 1.63% 1.67% 1.88%
Capitalization / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.42 x 2.22 x 2.03 x
EV / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.42 x 2.22 x 2.03 x
EV / EBITDA - - - 19.5 x 12.7 x 11.3 x 10.1 x
EV / FCF - -11.6 x -13.7 x - 17.7 x 40.3 x 18.8 x
FCF Yield - -8.62% -7.28% - 5.64% 2.48% 5.32%
Price to Book - 2.92 x 2.06 x 2.25 x 1.76 x 1.71 x 1.65 x
Nbr of stocks (in thousands) 216,534 252,085 252,412 253,029 253,029 - -
Reference price 2 16.04 18.60 13.42 15.22 12.26 12.26 12.26
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 960.2 1,151 1,163 1,199 1,284 1,396 1,527
EBITDA 1 - - - 197.2 245 274 307
EBIT 1 - 170.9 102.9 122.9 142.7 159.3 179.7
Operating Margin - 14.85% 8.85% 10.25% 11.11% 11.42% 11.77%
Earnings before Tax (EBT) 1 - 171.4 102.2 122.5 142.3 159 179.3
Net income 1 - 132.6 69.84 80.71 94 105.7 118.7
Net margin - 11.52% 6% 6.73% 7.32% 7.57% 7.77%
EPS 2 0.7000 0.5400 0.2700 0.3200 0.3767 0.4200 0.4700
Free Cash Flow 1 - -404 -246.6 - 175 77 165
FCF margin - -35.1% -21.2% - 13.63% 5.52% 10.81%
FCF Conversion (EBITDA) - - - - 71.43% 28.1% 53.75%
FCF Conversion (Net income) - - - - 186.17% 72.87% 139.04%
Dividend per Share 2 - 0.1600 0.1000 0.1000 0.2000 0.2050 0.2300
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -404 -247 - 175 77 165
ROE (net income / shareholders' equity) - 9.42% 4.3% 4.82% 5.22% 5.64% 6.07%
ROA (Net income/ Total Assets) - - - 2.88% 2.95% 2.96% 3.01%
Assets 1 - - - 2,806 3,186 3,570 3,942
Book Value Per Share 2 - 6.370 6.520 6.750 6.950 7.170 7.420
Cash Flow per Share 2 - - 0.3800 0.6100 0.9000 0.9800 1.120
Capex 1 - 493 342 215 278 263 248
Capex / Sales - 42.88% 29.4% 17.91% 21.65% 18.82% 16.24%
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Qingdao Vland Biotech INC.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.26
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
QINGDAO VLAND BIOTECH INC. Stock Qingdao Vland Biotech INC.
-19.45% 427M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.43% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.81% 114B
BIONTECH SE Stock BioNTech SE
-23.74% 19.42B
GENMAB A/S Stock Genmab A/S
-18.03% 16.2B
BEIGENE, LTD. Stock BeiGene, Ltd.
-19.97% 15.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-49.33% 14.19B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.08% 14.32B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.95% 14.31B
INSMED INCORPORATED Stock Insmed Incorporated
+126.04% 11.29B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 603739 Stock
  4. Financials Qingdao Vland Biotech INC.